Introduction
The course of epilepsy in children is most variable and the prognosis cannot be determined on the basis of age of onset, seizure types, interictal condition, electroencephalography (EEG) pattern or cause. The combination of age of onset, seizure types, interictal condition and EEG pattern, called epilepsy syndrome, however, does give some clue regarding cause and prognosis. It allows refined communication between caregivers. It is useful for research regarding treatment strategy and aetiology, including the eventual genetic background. Recent advances in basic epileptology reinforced this concept and led to the identification of specific cause for a given syndrome.
We will focus on new understanding of previously recognized syndromes and on new epilepsy syndromes.
Benign familial neonatal-infantile seizures
This condition is intermediate between benign familial neonatal convulsions (BFNCs) and benign familial infantile convulsions (BFICs), called benign familial neonatalinfantile seizures (BFNIS) [1] . The identification of these families is based on the mean age of onset, which ranges from that of BFNC to BFIC, from 2 days to 6 months. To date, a total of 10 families with mutations in SCN2A were reported. An Italian family with a strict phenotype of BFIC and a mutation in SCN2A suggested that BFNIS and BFIC show overlapping clinical features [2] . No SCN2A mutations are reported in families with BFNC although the neonatal onset is emphasized by a recent review of the clinical spectrum [3] .
Familial infantile convulsions and choreoathetosis
Benign familial infantile seizures with paroxysmal choreoathetosis inherited as an autosomal dominant trait were first recognized in 1997 [4] . Over 20 families have since been reported in different countries. Seizures appear at 3-12 months, and are partial and may secondarily generalize as previously described [5] . Seizures soon stop but paroxysmal choreoathetosis starts between 5 and 9 years. It occurs in paroxysmal attacks, at rest or induced by exercising and anxiety. Neurological examination and EEG tracings between these attacks are normal, as is psychomotor development. Genetic studies reveal a strong evidence of linkage to the pericentromeric region of chromosome 16. No causative gene has been found to date.
Seizures onset is between 4 and 30 months. Seizure manifestations are typical, characterized by cyanosis, staring and rare lateralizing signs, of short duration. There is a strong EEG marker, a spike followed by a bell-shaped slow-wave, localized in the midline regions, present in all subjects only during sleep. The prognosis is naturally favourable and the majority of patients do not require antiepileptic drugs (AEDs) [6] .
Epileptic encephalopathy with suppression bursts
This severe condition begins within the first 3 months of life. EEG demonstrates bursts of paroxysmal activity (polyspikes) lasting several seconds and alternating with episodes of flat or low amplitude tracing, a combination called suppression bursts. This pattern is present in both awake and sleep states, or mainly during sleep. It is associated with partial seizures variably combined with myoclonus or spasms.
The classification of the International League Against Epilepsy [7] recognized two conditions with suppression bursts: the early infantile epileptic encephalopathy (EIEE) or Ohtahara syndrome [8] and the neonatal myoclonic encephalopathy (EME) [9] .
In EIEE, there are spasms and the suppression burst pattern is often asymmetrical, mainly affecting the side of a cortical malformation, usually hemimegalencephaly or focal cortical dysplasia [8] . Aicardi syndrome, olivarydentate dysplasia and schizencephaly are other conditions in which such tracings are encountered [10] . In EME, there is no radiological evidence of a brain lesion, the patients exhibit erratic and massive myoclonus and there is familial recurrence [11] . Non-ketotic hyperglycinaemia, Menkes disease, pyridoxine and pyridoxal phosphate dependencies, and glutamate transporter defect [12] may be involved and share excess of glutamate transmission. Antiquitin, the gene for pyridoxine dependency causes an excessive renal excretion of a-aminoadipicsemi-aldehyde that chelates pyridoxine and causes the defect [13 ] .
Although the distinction between both entities is important from both the aetiologic and the therapeutic points of view, it may be difficult for a given patient since myoclonus and spasms may be confused at that age, because suppression bursts may be an early variant of fragmented hypsarrhythmia, and since all patients do not fulfil the criteria for either EIEE or EME [14] . Recently, a polyalanine expansion in the ARX gene (Aristales-related homeobox), longer than for infantile seizures, was observed in two unrelated cases of EIEE with normal brain MRI [15 ] .
Infantile spasms and West syndrome
The combination of clusters of spasms, psychomotor deterioration and hypsarrhythmia defines West syndrome that occurs mainly between 3 and 12 months of age.
Cryptogenic cases account for 9-15% of the cases, the rest being symptomatic. The symptomatic cases are associated with several prenatal, perinatal and postnatal factors. Various brain dysgenesis (lissencephaly, hemimegalencephaly, focal cortical dysplasia, septal dysplasia or callosal agenesis), chromosomal (including Down syndrome, del1p36) or single gene (mutations of ARX or STK9 gene) [16, 17 ] causes are reported. Untreated phenylketonuria, tetrahydrobiopterine deficiency and mitochondrial cytopathy including the NARP mutation are occasionally observed. Infantile spasms are particularly frequent in the course of Menkes disease.
Vigabatrin and steroids are the basis of treatment. Early treatment results in a better outcome [18] . Controlled studies in patients with other conditions than tuberous sclerosis found better short term but similar long term effect of steroids compared to vigabatrin, due to the high relapse rate with hormonal treatment [19] [20] [21] . Radiological work-up should be performed for surgery before going to topiramate that may have some effect [22] , although worsening has been reported [23] . The place of the ketogenic diet also needs to be determined [24] .
We reported a transient decrease of diffusion in subcortical structures in six patients with pharmacoresistant West syndrome of unknown cause. The eventuality of toxic lesions, including some inborn error of metabolism or drug toxicity, was considered but the contribution of the epileptic encephalopathy appears the most likely [25] .
Cryptogenic late-onset epileptic spasms
When cryptogenic, late onset epileptic spasms beginning between 12 and 48 months of age have a particular pattern that is intermediary between West and Lennox-Gastaut syndromes [26 ] . EEG does not show classical hypsarrhythmia but a temporal or temporofrontal slow wave or spike focus combined with slow spike-waves. Ictal events combine spasms in clusters, tonic seizures and atypical absences. Ictal EEG discloses a generalized high-voltage slow wave followed by diffuse voltage attenuation with superimposed fast activity, typical of the epileptic spasms, occurring in clusters. The classical treatment of infantile spasms was efficient in almost half the cases. This newly delineated cryptogenic syndrome is not merely a late variant of infantile seizures but could correspond to maturation dysfunction of the temporal lobes, in contrast with West syndrome combined with posterior and Lennox-Gastaut syndrome with anterior maturation features.
Malignant migrating partial seizures in infancy
First reported in 1995 in 14 infants [27] , malignant migrating partial seizure in infancy (MMPSI) is an epileptic encephalopathy characterized by onset in the first 6 months of life, of rapidly progressive partial seizures that become subcontinuous. Their onset migrates from one area of the cortex to the other and major deterioration of the psychomotor abilities appears. Cases were later identified in European, Asian and American countries.
Early seizures have motor and autonomic components, later seizures are more polymorphic, varying from one seizure to the next in a given patient. Seizures last several minutes longer than usual partial seizures in infancy. They tend to be more frequently generalized as time goes by. Myoclonus is rare, and spasms exceptional. By the end of the first year of life, seizures become almost continuous and occur in clusters: seizures lasting several weeks, during which the infant deteriorates considerably, and followed by disappearance of seizures during a few weeks with slow improvement of the condition. Microcephaly progressively occurs.
To date, no cause has been identified by historical, biochemical, radiological or histological investigations. No familial case or consanguinity has been reported. A genetic study failed to find mutations in sodium (SCN1A, SCN2A), potassium (KCNQ2, KCNQ3), and chloride (CLCN2) ion channels in three children with migrating partial seizures in infancy [28 ] .
The course is most severe because seizures never come under control. For the rare patients whose seizures are controlled before the end of the first year of life, walking is possible. Only a single patient, however, is said to have had normal development at age 7 years [29] and levetiracetam was reported recently in a possible case with early neonatal onset [30] . This contrast in the course raises doubts regarding the syndromic diagnosis for these patients. Open data on the effect of the combination of clonazepam and stiripentol have been reported. Bromide may be efficient but AEDs for partial epilepsy, mainly carbamazepine and vigabatrin, seem to worsen the condition.
Dravet syndrome
First described in 1978, Dravet syndrome is characterized by the occurrence, in an otherwise normal infant, of generalized or unilateral clonic or tonic-clonic seizures, mostly with fever, in the first year of life [31] . Later, other seizure types occur, including myoclonus, atypical absences and partial seizures. Developmental delay progressively appears from the second year. Seizures remain fever sensitive and tend to evolve to status epilepticus [32] . The term Dravet syndrome is preferred to that of severe myoclonic epilepsy in infancy since all patients do not develop myoclonia. The first seizure can be mistaken for complex febrile seizures, although early recurrence allows the distinction. This sensitivity to fever seizures led to the identification of mutations in SCN1A [33] , a gene first described in families with generalized epilepsy with febrile seizures plus (GEFSþ) [34] . Febrile seizures plus (FSþ) defined febrile seizures lasting beyond 6 years or associated with non-febrile seizures [35] . Dravet syndrome was proposed as the most severe form of the spectrum of the FSþ linked epilepsies. SCN1A mutations account for 75% of Dravet syndrome cases. Recently, almost 10% of patients with reported negative mutations showed partial or complete deletion of the gene and less frequently duplication [36, 37 ] . Inherited cases were also reported with parental mosaicism [38 ,39] . SCN1A mutations were shown to cause vaccine encephalopathies [40 ] .
Seizures in Dravet syndrome are highly pharmacoresistant. The ultimate goal is to reduce seizures, mainly status epilepticus, during the first years [41] . A prospective randomized trial [42] proved the efficacy of the association of clobazam, valproate and stiripentol in reducing status epilepticus and the frequency of tonic-clonic seizures. In patients responding partially, the adjunction of topiramate or levetiracetam might be effective.
The incidence of hippocampal lesions [43] could be underestimated. A T2 weighted coronal MRI performed after the second or third year of life could help in disclosure.
The mechanism of sudden death that is particularly frequent in this syndrome may result from the SCN1A mutation [44] .
Myoclonic astatic epilepsy
The patients collected under the term 'centrencephalic myoclonic-astatic petit mal', because they were supposed to share a genetic predisposition related to idiopathic generalized epilepsy, combine generalized tonic-clonic seizures, myoclonus and generalized spike-waves [45] . The condition consists of an aetiological concept sharing features of the Lennox-Gastaut syndrome although there is no brain lesion, pharmacoresistance, episodes of status epilepticus and impact on cognitive functions. It comprises several subgroups, each subgroup consisting of an epilepsy syndrome reported as the Dravet syndrome [32] , 'benign Epileptic syndromes in childhood Nabbout and Dulac 163 myoclonic epilepsy in infancy' [32] , and cases that begin in school age with myoclonic-astatic seizures.
Myoclonic astatic epilepsy (MAE) begins between 2 and 5 years, often explosively, with either tonic-clonic seizures or drop attacks. A first tonic-clonic seizure at that age requires an EEG and treatment in cases of spike wave activity. Multiple seizure types include myoclonic-astatic, tonic-clonic and absences. Non-convulsive status epilepticus is a classically underdiagnosed complication. Tonic seizures are a risk factor for poor prognosis [46] . Cognitive deterioration is distinct from that observed in Lennox-Gastaut and usually combines apraxia and dysarthria. This predominance is explained by the major involvement of the rolandic strip that contributes to generate the myoclonus.
A genetic predisposition plays a role in MAE. Very few cases were reported in families affected by febrile seizures plus with mutations in GEFSþ genes [34, 47] . In a study of 22 sporadic patients affected with MAE, however, no mutation was found in the three major GEFSþ genes (SCN1A, SCN1B and GABRG2) [48] . MAE has a different genetic background than Dravet syndrome and may be inherited as a polygenic disorder involving different families of genes.
The course is variable. Most patients recover within 1-3 years but others develop myoclonic status and major cognitive decline in the context of an epileptic encephalopathy. Therapy for epilepsy with myoclonic-astatic seizures in early childhood remains empirical. Some compounds may worsen the condition: phenytoin, carbamazepine, and vigabatrin [49] . Valproate, ethosuximide and benzodiazepines (clobazam more than clonazepam) have been used successfully. The most efficient combination, however, seems to be valproate with lamotrigine [50] . The use of benzodiazepines should be restricted to episodes of myoclonic status epilepticus. Pharmacoresistance is frequent, however, in patients who develop epileptic encephalopathy, in the sense of cognitive and motor deterioration with ongoing tonic and myoclonic seizures. A ketogenic diet should be started as soon as such a course is identified [51, 52] . In non-responders to the diet and in those who do not tolerate it, the indication of steroids should be considered. The dose needs to be moderate, however, in order to avoid precipitation of convulsive seizures. The treatment needs to be prolonged in order to prevent relapse during the period of risk, which lasts 1-2 years.
Epileptic encephalopathy with continuous spike waves in slow sleep
This condition was initially reported with over 85% of slow wave sleep with spike waves. It was later recognized to occur with lower spiking activity in various conditions, namely worsening of idiopathic focal epilepsy in childhood also called atypical benign focal epilepsy, with negative myoclonus or facial dyspraxia [53, 54] , symptomatic epilepsy usually due to vascular prenatal or perinatal lesions involving the rolandic area and eventually the thalamus, cryptogenic involving the temporal lobe with aphasia and auditory agnosia [55, 56] or the frontal lobes with frontal syndrome [57] . The story of a clear motor or cognitive deterioration is crucial for diagnosis and therapeutic strategy. Expressive dysphasia has been related to an SRPX2 monogenic mutation [58 ] .
Devastating epileptic encephalopathy in school aged children
Devastating epileptic encephalopathy in school aged children (DESC) presents in previously normal children as intractable convulsive status epilepticus lasting several weeks and followed without a silent period by pharmacoresistant perisylvian epilepsy associated with a dramatic deterioration of cognitive function that predominates on temporal lobe function [59 ] . It begins between 4 and 11 years, with fever without evidence of intracranial infection, and intractable status epilepticus followed immediately by pharmacoresistant epilepsy with clinical and EEG evidence of perisylvian involvement, bilateral temporal and frontal dysfunction on neuropsychological tests predominating on limbic structures, consistent with MRI and PET findings. This condition easily goes unrecognized since it presents in a febrile setting and can be easily diagnosed as 'grey matter encephalitis' [60, 61] .
There is no evidence of brain inflammation whereas status epilepticus causes bilateral temporal epileptogenic lesions: it may merely be a previously overlooked epileptic encephalopathy. Another non-inflammatory epileptic encephalopathy triggered by fever with massive involvement of both frontal lobes has been reported [62 ] .
Conclusion
The concept of epilepsy syndromes, developed four decades ago by the school of Marseille [63] and established by the International League Against Epilepsy [7] , remains a golden standard in paediatric epileptology. The Dravet syndrome was described on clinical and EEG criteria long before the basic mechanism, a mutation in SCN1A gene was recently identified. Clinical and EEG delineation from MAE was confirmed by a different genetic background. 
